These findings indicate that co‐administration of ABC294640 and ABT‐199 markedly reduces in vivo myeloma tumor growth associated with the down‐regulation of Mcl‐1, c‐Myc, Bcl‐2, and Bcl‐xL. Here, BCL2 is linked to neoplasm.